Blog Hero

Resources

Join the Community
Product Information •

Redefining Standards of Care: A Data-Driven Look at Systane® PRO PF

Over-the-counter drops remain a cornerstone of dry eye treatment—but only if they are tailored, evidence-based, and designed to stabilize the tear film and support ocular surface health, as TFOS DEWS III emphasizes. With Systane® PRO PF, patients experience a unique formula that is designed to address all types of dry eye disease.    Formulated with a triple-action blend—including an…
Education & Awareness, Product Information •

Controlling your Dry Eye Disease: Significance of Compliance 

By Dr. Diana Nguyen  If you’re living with dry eye disease, you know how uncomfortable it can be with burning, irritation, redness, or that gritty “sand in your eyes” feeling. What many people don’t realize is that dry eye is a chronic disease that can’t be cured with a quick fix. It is a chronic disease that requires building healthy, consistent habits at home to…
Infographics, Product Information •

A Closer Look at Dry Eye Disease

A prevalent study out of Ontario invited patients to complete a questionnaire on dry eye. Over 5,000 patients completed the questionnaire, and those with scores higher than six were classified as having dry eye disease (DED). The findings showed that up to 21% of Canadians may be affected by DED1.   With the prevalence of DED, eye care professionals (ECPs) are always on the lookout for innovative and insightful treatment options; XIIDRA is the first…
Product Information •

TFOS DEWS III Is Here: Is Your Practice Ready to Evolve Beyond Artificial Tears?  

The landscape of dry eye management has shifted. With the release of the TFOS DEWS III: Diagnostic Methodology report, the clinical consensus is clearer than ever: dry eye disease (DED) is a complex, progressive loss of ocular surface homeostasis requiring targeted, etiology-driven intervention.  Yet, patients are still managing DED with over-the-counter artificial tears, masking progressive tissue damage while their underlying drivers go…
Product Information •

TFOS DEWS III: What Actually Changes for Your Dry Eye Practice 

Eight years after the landmark Tear Film and Ocular Surface Society TFOS) DEWS II reports, the TFOS has consolidated the evidence again. The TFOS DEWS III Management and Therapy Report, published in the American Journal of Ophthalmology (Jones et all., 2025), reflects the volume of work published since 2017. For Canadian optometrists, the headline is encouraging: the framework is now simpler to apply at the chair, and…
Education & Awareness, Wellness & Lifestyle •

From Nine Tests to Three Steps: Professor James Wolffsohn on DEWS III

Sponsored by Espanione Group   One in three adults carries a dry eye diagnosis, and most are still underdiagnosed and undertreated. TFOS DEWS III is the most significant update to how we define, diagnose and treat the disease, and is genuinely easier to use at the chair.  Join Professor James Wolffsohn, Professor and Dean of Optometry at Aston University and a member of…

Privacy Policy

Sitemap

Terms and Conditions

instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax